XEGLYZE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XEGLYZE (XEGLYZE).
Glucagon-like peptide-1 (GLP-1) receptor agonist; enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
| Metabolism | Primary proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP), followed by renal excretion of metabolites. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70% of elimination, with biliary/fecal elimination contributing about 30%. |
| Half-life | Terminal elimination half-life is 12 hours, supporting once-daily dosing in patients with normal renal function. |
| Protein binding | 95% bound to albumin. |
| Volume of Distribution | Vd is 0.8 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Oral bioavailability is 85%; not administered by other routes. |
| Onset of Action | Oral: 2 hours to detectable glucose lowering; maximal effect by 4–6 hours. |
| Duration of Action | Duration of action is 12–14 hours, allowing once-daily dosing; continued effect requires daily administration. |
| Molecular Weight | 398.5 |
100 mg orally once daily.
| Dosage form | LOTION |
| Renal impairment | eGFR ≥60 mL/min/1.73 m²: No adjustment. eGFR 45-59: 75 mg once daily. eGFR 30-44: 50 mg once daily. eGFR <30: Not recommended. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: 50 mg once daily. Child-Pugh Class C: Not recommended. |
| Pediatric use | Not established; safety and efficacy in pediatric patients under 18 years have not been studied. |
| Geriatric use | No specific dose adjustment recommended based on age alone; monitor renal function closely. |
| 1st trimester | Avoid due to potential teratogenicity observed in animal studies; no adequate human studies. |
| 2nd trimester | Use only if benefit outweighs risk; limited data suggest possible fetal growth restriction. |
| 3rd trimester | Use only if clearly needed; may cause neonatal hypoglycemia if used near term. |
Clinical note
Comprehensive clinical and safety monograph for XEGLYZE (XEGLYZE).
| Placental transfer | Crosses placenta in animal models; molecular weight <500 Da suggests transfer in humans. |
| Breastfeeding | Excreted into breast milk in low concentrations; monitor infant for hypoglycemia and gastrointestinal effects. Caution in preterm or ill infants. |
| Lactation Rating |
■ FDA Black Box Warning
Risk of thyroid C-cell tumors, including medullary thyroid carcinoma; contraindicated in patients with personal or family history of MTC or MEN-2.
| Serious Effects |
Type 1 diabetes mellitusDiabetic ketoacidosisSevere renal impairment (eGFR <30 mL/min/1.73m2)
| Precautions | Pancreatitis, Diabetic retinopathy complications, Hypoglycemia when used with insulin or sulfonylureas, Renal impairment, Acute kidney injury, Severe gastrointestinal disease |
| Food/Dietary | XEGLYZE slows gastric emptying, which may delay absorption of oral medications. Take oral contraceptives and other time-critical drugs at least 1 hour before injection or 4 hours after. No specific food restrictions, but high-fat meals may exacerbate gastrointestinal side effects. Avoid grapefruit as it may increase drug exposure via CYP3A4 inhibition. |
Loading safety data…
| L3 |
| Teratogenic Risk | First trimester: Animal studies show increased risk of malformations, including cardiac and neural tube defects; human data limited but suggest potential teratogenicity. Second and third trimesters: Risk of fetotoxicity (growth restriction) and neonatal hypoglycemia with exposure near term. |
| Fetal Monitoring | Monitor maternal blood glucose, renal function, and liver enzymes; fetal surveillance includes growth ultrasound and nonstress test; neonatal monitoring for hypoglycemia and respiratory adaptation. |
| Fertility Effects | No known negative impact on male or female fertility in animal studies; human data limited. Use caution in women attempting conception due to potential early embryonic effects. |
| Clinical Pearls | XEGLYZE (inzomelide) is a GLP-1 receptor agonist with a half-life of 7 days, allowing weekly subcutaneous dosing. Monitor for delayed gastric emptying; consider holding prior to elective surgeries requiring general anesthesia due to aspiration risk. Dose adjustment not required in renal impairment but contraindicated if eGFR <15 mL/min/1.73m2. Do not initiate during acute pancreatitis; discontinue if pancreatitis suspected. |
| Patient Advice | Inject subcutaneously in abdomen, thigh, or upper arm once weekly on the same day. Rotate injection sites. · Store in refrigerator (2-8°C); allow to reach room temperature for 30 minutes before injection. Do not freeze. · Take missed dose within 3 days if remembered; if >3 days, skip and resume next scheduled dose. · Common side effects include nausea, vomiting, diarrhea, and decreased appetite; these often improve over time. · Seek immediate medical care for severe abdominal pain (possible pancreatitis) or vision changes (possible retinopathy). · Do not share pens; use a new needle for each injection. |